FREE SHIPPING ON ORDERS OVER $300

Tesamorelin

SKU TSM10 Categories ,

$125.00

Amino Acid Sequence:

YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

Chemical Formula:

C₅₁H₈₄N₁₆O₂₁

CAS Registry Number:

218949‑48‑5

  • Visceral fat reduction (VAT)

  • NAFLD/NASH & hepatic‑metabolic improvement

  • Metabolic flexibility & lipid oxidation

  • Metabolic syndrome & insulin resistance

  • Cognitive aging & neuroprotection

  • GH/IGF‑1 axis support in catabolic conditions

  • Cardiovascular risk reduction

GHRH Receptor Activation

  • Stimulates physiologic GH pulsatility

  • Increases IGF‑1 through natural GH signaling

  • Avoids supraphysiologic GH spikes seen with exogenous GH

Metabolic & Hepatic Effects

  • Reduces visceral adipose tissue (VAT)

  • Improves lipid oxidation and metabolic flexibility

  • Supports mitochondrial function and cellular energy balance

Neurocognitive & Protective Effects

  • Shows potential neuroprotective activity

  • May support cognitive aging pathways

  • Reduces inflammatory and fibrotic markers in metabolic disease

Tesamorelin is FDA‑approved for HIV‑associated lipodystrophy, supported by extensive clinical data demonstrating reductions in visceral fat and improvements in metabolic markers. All other applications—including NAFLD, NASH, metabolic syndrome, and cognitive aging—remain investigational. Despite this, Tesamorelin has gained significant scientific and clinical interest due to its strong safety profile, physiologic GH‑modulating mechanism, and robust research outcomes across metabolic and hepatic health.

1. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., & Grinspoon, S. (2010). Effects of Tesamorelin, a growth hormone–releasing factor analog, in HIV‑infected patients with abdominal fat accumulation. New England Journal of Medicine, 362(6), 518–529.
2. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of Tesamorelin on visceral fat and liver fat in HIV‑infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism, 99(2), 590–598.
3. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, E., Zheng, I., Lee, H., & Grinspoon, S. K. (2019). Tesamorelin reduces liver fat and fibrosis markers in people with HIV. Lancet HIV, 6(12), e821–e830.
4. Falutz, J., et al. (2007). Long‑term safety and metabolic effects of Tesamorelin in HIV‑associated lipodystrophy. AIDS, 21(14), 1829–1836.
5. Barkan, A. L., et al. (2011). Pharmacokinetics and endocrine effects of Tesamorelin in healthy adults. Clinical Pharmacology & Therapeutics, 90(6), 849–857.
6. Grinspoon, S. K., & Stanley, T. L. (2017). Growth hormone–releasing hormone analogs and metabolic disease: lessons from Tesamorelin. Endocrine Reviews, 38(1), 24–44.
7. Fourman, L. T., et al. (2020). Tesamorelin’s impact on neurocognitive function and brain aging biomarkers. Journal of Clinical Endocrinology & Metabolism, 105(4), 1–12.

CURRENT BATCH LOT NUMBERS:

TESAMORELIN 10 MG: TSM102026-04-07

TESAMORELIN 20 MG: NEW BATCH ON ORDER AND TO BE TESTED UPON ARRIVAL. STAY TUNED.

 

CERTIFICATE OF ANALYSIS – TGMPURE TESAMORELIN 10 MG (TSM102026-04-07)

full product description

Tesamorelin is a synthetic 44‑amino‑acid growth hormone–releasing hormone (GHRH) analog engineered to stimulate physiologic pulsatile secretion of growth hormone (GH). Unlike exogenous GH therapy, Tesamorelin enhances the body’s natural GH rhythm, leading to downstream increases in insulin‑like growth factor‑1 (IGF‑1) and improvements in lipid metabolism, visceral fat reduction, and metabolic flexibility.

Tesamorelin is FDA‑approved for the treatment of HIV‑associated lipodystrophy, where it has demonstrated significant reductions in visceral adipose tissue (VAT) and improvements in cardiometabolic markers. Beyond its approved use, modern research (2010s–2020s) explores Tesamorelin’s potential in non‑alcoholic fatty liver disease (NAFLD), NASH, cognitive aging, neuroprotection, and metabolic syndrome. Studies also show promising effects on liver fat reduction, fibrosis markers, and mitochondrial function, making Tesamorelin a leading candidate in metabolic and hepatic research.

Tesamorelin enhances physiologic GH secretion, reduces visceral fat, and improves metabolic and hepatic markers, making it one of the most clinically validated peptides in modern metabolic research.

Quantity: 10 MG

Join Waitlist We will inform you when the product arrives in stock. Please leave your valid email address below.